search
Back to results

"Lumbar Operatively Inserted PerQdisc Artificial Implant Following Nulcectomy" (LOPAIN2) (LOPAIN2)

Primary Purpose

Degenerative Disc Disease, Chronic Low-back Pain

Status
Recruiting
Phase
Not Applicable
Locations
International
Study Type
Interventional
Intervention
PerQdisc Nucleus Replacement System
Sponsored by
Spinal Stabilization Technologies
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Degenerative Disc Disease focused on measuring Degenerative Disc Disease, DDD, Chronic Low Back Pain, cLBP, Disc Herniation, Nucleus Replacement, Low Back Pain

Eligibility Criteria

21 Years - undefined (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  • Patient is skeletally mature and at least 21 years of age.
  • Patient has Degenerative Disc Disease (DDD) at one or more levels between L1 and S1 but the discogenic pain must be limited to a single level.
  • Patient has adequate disc height (6mm) at the level to be treated
  • Patient is not responsive to conservative, non-surgical treatment for back pain.
  • Patient has signed the approved Informed Consent Form.
  • All surgeries must be approved by the Medical Advisory Board (MAB) Exclusion Criteria:• Patient has less than 6 mm of disc height.
  • Patient has had prior lumbar spine surgery (nucleoplasty at non-index level is considered acceptable).
  • Patient has had spinal fusion in the lumbar or thoracic intervertebral spaces. Cervical fusion is allowed as long as there are no neurologic deficits in the lower extremities.
  • Patient has spondyloarthropathy or other spondylolisthesis greater than 2 mm.
  • Patient has congenital moderate or severe spinal stenosis or epidural lipomatosis.• Patient has significant facet disease. Significant is defined as pain improvement of 80% or more following image-guided medial branch blocks of the target level according to SIS guidelines (diagnostic, contrast controlled).
  • Patient has any known active malignancy.
  • Patient has previously undergone or currently on immunosuppressive therapy. Steroids used to treat inflammation are allowed.
  • Patient has active or local systemic infection.
  • Patient has been diagnosed with hepatitis, rheumatoid arthritis, lupus erythematosus, or other autoimmune disease including AIDS, ARC and HIV.
  • Patient has diabetes mellitus (Type 1 or 2) requiring daily insulin management.
  • Patient has osteopenia of the spine (T-score of -1.0 or lower). A DEXA scan should be performed to rule out patients considered at risk for osteopenia.• Patient has morbid obesity defined as a body mass index (BMI) more than 40 or a weight of more than 45 kg (100 lbs.) over ideal body weight.
  • Patient has a known allergy to silicone or barium sulfate.
  • Patient has a significant disc herniation at the level to be treated. Significant is defined as a large, extruded herniation that creates a risk for expulsion.
  • Patient has a significant Schmorl's node in the level to be treated. Significant is defined as a large, rectangular or irregular shaped node that has an associated active inflammatory process (Modic I changes).
  • Patient has motion of less than 3 degrees on pre-operative lateral flexion/extension radiographs.
  • Patient belongs to a vulnerable population or has a condition such that his/her ability to provide informed consent, comply with follow-up requirements, or provide self-assessments is compromised (e.g. developmentally disabled, prisoner, chronic alcohol/ substance abuser)

Intraoperative Exclusion Criteria:

  • Protrusion of the 20A Imaging Balloon up to or beyond the outer margin of the vertebra during the imaging steps.
  • Patient has a violated endplate as determined by imaging balloons during fluoroscopy.
  • Patient has a disc space that is too narrow for implantation.

Sites / Locations

  • CIGE: Centro de Imunologia y GeneticaRecruiting
  • Fundacion Hospitalaria San Vicente de PaulRecruiting
  • Cediul S.A.Recruiting
  • Fundación Campbell
  • Sabbag Radiólogos S.A.
  • Sociedad de Cirugia de Bogota- Hospital de San JoseRecruiting
  • Clínica Imbanaco de Cali S.A.Recruiting
  • Sanatario AmericanoRecruiting

Arms of the Study

Arm 1

Arm Type

Experimental

Arm Label

Lumbar Disc Nucleus Replacement

Arm Description

All patients meeting all inclusion criteria and no exclusion criteria will be considered for nucleus replacement surgery following a review by the Medical Advisory Board.

Outcomes

Primary Outcome Measures

Perfromance: ODI
Change in in Oswestry Disability Index (ODI) comparing baseline to follow up visits using a patient-reported outcome tool
Perfromance: ODI
Change in in Oswestry Disability Index (ODI) comparing baseline to follow up visits using a patient-reported outcome tool
Performance: VAS
Change in back pain as measured by the 100 - millimeter Visual Analog Scale (VAS)
Performance: VAS
Change in back pain as measured by the 100 - millimeter Visual Analog Scale (VAS)
Safety: Expulsion & Device Failure
Incidence of device expulsion and device failure following surgery based on follow up X-rays and MRI's
Safety: Expulsion & Device Failure
Incidence of device expulsion and device failure following surgery based on follow up X-rays and MRI's

Secondary Outcome Measures

Safety: Revision Surgery
Incidence of revision surgery
Safety: Expulsion & Device Failure
Incidence of device expulsion and device failure following surgery based on follow up X-rays and MRI's
Performance: Disc Height
Preservation of intervertebral disc height (in mm) as measured on MRI post-surgery compared to baseline
Performance: RoM
Preservation of range of movement (expressed in degrees) at the index and adjacent levels at baseline compared to follow-up using flexion/extension radiographs
Safety: Neurological Status
Maintenance of baseline neurologic status through physical assessment evaluating nerve compression at baseline and post-surgical follow-up using pain, motor strength, and sensation feedback from the patient on a 0 (no compression) to 5 (major compression) scale
Performance: Analgesic Score
Change in level of pain medication used comparing baseline to follow up visits based on a medication scale ranging from 0 (no meds) - 4 (high dose opioids)
Safety: SAE
Incidence of serious adverse events that are related to the surgical procedure or Incidence of Serious Adverse Events related to the surgical procedure or device

Full Information

First Posted
August 1, 2022
Last Updated
February 9, 2023
Sponsor
Spinal Stabilization Technologies
search

1. Study Identification

Unique Protocol Identification Number
NCT05508360
Brief Title
"Lumbar Operatively Inserted PerQdisc Artificial Implant Following Nulcectomy" (LOPAIN2)
Acronym
LOPAIN2
Official Title
"Lumbar Operatively Inserted PerQdisc Artificial Implant Following Nulcectomy" (LOPAIN2)
Study Type
Interventional

2. Study Status

Record Verification Date
February 2023
Overall Recruitment Status
Recruiting
Study Start Date
August 22, 2022 (Actual)
Primary Completion Date
August 22, 2024 (Anticipated)
Study Completion Date
August 22, 2029 (Anticipated)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Spinal Stabilization Technologies

4. Oversight

Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
Yes

5. Study Description

Brief Summary
This study will be a prospective, open-label, multi-center study including 72 patients that will collect additional safety and efficacy data for the Spinal Stabilization Technologies PerQdisc Nucleus Replacement System.
Detailed Description
This study will be a prospective, open-label, multi-center study that will collect additional safety and efficacy data for the minimally invasive PerQdisc Nucleus Replacement Device (NRD). Patients will have degenerative disc disease (DDD) in one or more lumbar discs. The NRD is used for surgical replacement of a single nucleus pulposus between spinal lumbar discs L1-S1 using an anterior or lateral transpsoas approach. Currently the surgical gold standard involves spinal fusion of the affected vertebral bodies, reducing range of motion and increasing stress on other vertebral bodies. The goal of nucleus replacement is to reduce chronic low back pain by maintaining disc height while preserving range of motion.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Degenerative Disc Disease, Chronic Low-back Pain
Keywords
Degenerative Disc Disease, DDD, Chronic Low Back Pain, cLBP, Disc Herniation, Nucleus Replacement, Low Back Pain

7. Study Design

Primary Purpose
Treatment
Study Phase
Not Applicable
Interventional Study Model
Single Group Assignment
Model Description
This is an open-label study. Patients will receive one implant if they meet all inclusion/exclusion criteria after a review by the Medical Advisory Board (MAB).
Masking
None (Open Label)
Allocation
N/A
Enrollment
72 (Anticipated)

8. Arms, Groups, and Interventions

Arm Title
Lumbar Disc Nucleus Replacement
Arm Type
Experimental
Arm Description
All patients meeting all inclusion criteria and no exclusion criteria will be considered for nucleus replacement surgery following a review by the Medical Advisory Board.
Intervention Type
Device
Intervention Name(s)
PerQdisc Nucleus Replacement System
Intervention Description
Lumbar spine disc nucleus replacement system. All patients meeting all inclusion criteria and no exclusion criteria will be considered for nucleus replacement surgery following a review by the Medical Advisory Board.
Primary Outcome Measure Information:
Title
Perfromance: ODI
Description
Change in in Oswestry Disability Index (ODI) comparing baseline to follow up visits using a patient-reported outcome tool
Time Frame
6 months
Title
Perfromance: ODI
Description
Change in in Oswestry Disability Index (ODI) comparing baseline to follow up visits using a patient-reported outcome tool
Time Frame
12 months
Title
Performance: VAS
Description
Change in back pain as measured by the 100 - millimeter Visual Analog Scale (VAS)
Time Frame
6 months
Title
Performance: VAS
Description
Change in back pain as measured by the 100 - millimeter Visual Analog Scale (VAS)
Time Frame
12 months
Title
Safety: Expulsion & Device Failure
Description
Incidence of device expulsion and device failure following surgery based on follow up X-rays and MRI's
Time Frame
6 months
Title
Safety: Expulsion & Device Failure
Description
Incidence of device expulsion and device failure following surgery based on follow up X-rays and MRI's
Time Frame
12 months
Secondary Outcome Measure Information:
Title
Safety: Revision Surgery
Description
Incidence of revision surgery
Time Frame
6 months, 12 months, and 5 years
Title
Safety: Expulsion & Device Failure
Description
Incidence of device expulsion and device failure following surgery based on follow up X-rays and MRI's
Time Frame
5 years
Title
Performance: Disc Height
Description
Preservation of intervertebral disc height (in mm) as measured on MRI post-surgery compared to baseline
Time Frame
6 months, 12 months, and 5 years
Title
Performance: RoM
Description
Preservation of range of movement (expressed in degrees) at the index and adjacent levels at baseline compared to follow-up using flexion/extension radiographs
Time Frame
6 months, 12 months, 5 years
Title
Safety: Neurological Status
Description
Maintenance of baseline neurologic status through physical assessment evaluating nerve compression at baseline and post-surgical follow-up using pain, motor strength, and sensation feedback from the patient on a 0 (no compression) to 5 (major compression) scale
Time Frame
6 months, 12 months, and 5 years
Title
Performance: Analgesic Score
Description
Change in level of pain medication used comparing baseline to follow up visits based on a medication scale ranging from 0 (no meds) - 4 (high dose opioids)
Time Frame
6 months, 12 months, and 5 years
Title
Safety: SAE
Description
Incidence of serious adverse events that are related to the surgical procedure or Incidence of Serious Adverse Events related to the surgical procedure or device
Time Frame
6 months, 12 months, and 5 years

10. Eligibility

Sex
All
Minimum Age & Unit of Time
21 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Patient is skeletally mature and at least 21 years of age. Patient has Degenerative Disc Disease (DDD) at one or more levels between L1 and S1 but the discogenic pain must be limited to a single level. Patient has adequate disc height (6mm) at the level to be treated Patient is not responsive to conservative, non-surgical treatment for back pain. Patient has signed the approved Informed Consent Form. All surgeries must be approved by the Medical Advisory Board (MAB) Exclusion Criteria:• Patient has less than 6 mm of disc height. Patient has had prior lumbar spine surgery (nucleoplasty at non-index level is considered acceptable). Patient has had spinal fusion in the lumbar or thoracic intervertebral spaces. Cervical fusion is allowed as long as there are no neurologic deficits in the lower extremities. Patient has spondyloarthropathy or other spondylolisthesis greater than 2 mm. Patient has congenital moderate or severe spinal stenosis or epidural lipomatosis.• Patient has significant facet disease. Significant is defined as pain improvement of 80% or more following image-guided medial branch blocks of the target level according to SIS guidelines (diagnostic, contrast controlled). Patient has any known active malignancy. Patient has previously undergone or currently on immunosuppressive therapy. Steroids used to treat inflammation are allowed. Patient has active or local systemic infection. Patient has been diagnosed with hepatitis, rheumatoid arthritis, lupus erythematosus, or other autoimmune disease including AIDS, ARC and HIV. Patient has diabetes mellitus (Type 1 or 2) requiring daily insulin management. Patient has osteopenia of the spine (T-score of -1.0 or lower). A DEXA scan should be performed to rule out patients considered at risk for osteopenia.• Patient has morbid obesity defined as a body mass index (BMI) more than 40 or a weight of more than 45 kg (100 lbs.) over ideal body weight. Patient has a known allergy to silicone or barium sulfate. Patient has a significant disc herniation at the level to be treated. Significant is defined as a large, extruded herniation that creates a risk for expulsion. Patient has a significant Schmorl's node in the level to be treated. Significant is defined as a large, rectangular or irregular shaped node that has an associated active inflammatory process (Modic I changes). Patient has motion of less than 3 degrees on pre-operative lateral flexion/extension radiographs. Patient belongs to a vulnerable population or has a condition such that his/her ability to provide informed consent, comply with follow-up requirements, or provide self-assessments is compromised (e.g. developmentally disabled, prisoner, chronic alcohol/ substance abuser) Intraoperative Exclusion Criteria: Protrusion of the 20A Imaging Balloon up to or beyond the outer margin of the vertebra during the imaging steps. Patient has a violated endplate as determined by imaging balloons during fluoroscopy. Patient has a disc space that is too narrow for implantation.
Central Contact Person:
First Name & Middle Initial & Last Name or Official Title & Degree
Andy Murillo
Phone
1 (210) 632-5444
Email
amurillo@sstspine.com
First Name & Middle Initial & Last Name or Official Title & Degree
Molly Bond
Phone
1 (715) 577-7527
Email
mbond@sstspine.com
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Jeff Golan, MD
Organizational Affiliation
Jewish General Hospital
Official's Role
Study Chair
First Name & Middle Initial & Last Name & Degree
Michael Hess, MD
Organizational Affiliation
London Spine Clinic/ATOS-Klinik
Official's Role
Study Chair
Facility Information:
Facility Name
CIGE: Centro de Imunologia y Genetica
City
Medellín
State/Province
Antioquia
Country
Colombia
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Julian Zuluaga, M.D.
First Name & Middle Initial & Last Name & Degree
Julian Zuluaga, M.D.
Facility Name
Fundacion Hospitalaria San Vicente de Paul
City
Medellín
State/Province
Antioquia
Country
Colombia
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Alejandra Mazo
Email
alejandra.mazo@sanvicentsfundacion.com
First Name & Middle Initial & Last Name & Degree
Eloy Barrios, MD
Facility Name
Cediul S.A.
City
Barranquilla
State/Province
Atlantico
Country
Colombia
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Yolanda Muvdi
Email
eclinicos2@cediul.com
First Name & Middle Initial & Last Name & Degree
Salvador Mattar, MD
Facility Name
Fundación Campbell
City
Barranquilla
State/Province
Atlantico
Country
Colombia
Individual Site Status
Active, not recruiting
Facility Name
Sabbag Radiólogos S.A.
City
Barranquilla
State/Province
Atlantico
Country
Colombia
Individual Site Status
Active, not recruiting
Facility Name
Sociedad de Cirugia de Bogota- Hospital de San Jose
City
Bogotá
State/Province
D.c.
Country
Colombia
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Laura Alvarado
Email
Coordinacionestudios@hospitalsanjose.org
First Name & Middle Initial & Last Name & Degree
Rodolfo Paez, MD
Facility Name
Clínica Imbanaco de Cali S.A.
City
Cali
State/Province
Valle Del Cauca
Country
Colombia
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Monica Dominguez
Email
monica.dominguez@imbanaco.com
First Name & Middle Initial & Last Name & Degree
Eduardo Walteros, MD
Facility Name
Sanatario Americano
City
Asunción
ZIP/Postal Code
1101
Country
Paraguay
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Carlos Cetraro
Email
radiosolutionspy@gmail.com
First Name & Middle Initial & Last Name & Degree
Francisco Duarte, MD

12. IPD Sharing Statement

Plan to Share IPD
No

Learn more about this trial

"Lumbar Operatively Inserted PerQdisc Artificial Implant Following Nulcectomy" (LOPAIN2)

We'll reach out to this number within 24 hrs